Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

19
Your Daily Pharma Scoop: Exelixis Publishes Positive Data, Stellar Trial Succeeds, Kalytera's Pre-IND Meet

2018-07-07 seekingalpha
Exelixis (EXEL) announced results from the Phase 3 clinical trial of Cabometyx (cabozantinib) in treatment-experienced patients with hepatocellular carcinoma (‘HCC). The results were published in the New England Journal of Medicine (‘NEJM). Median overall survival (‘OS) showed statistically significant improvement over placebo. OS for Cabometyx was 10.2 months while that for placebo was 8 months. Median progression-free survival (‘PFS) too showed significant improvement.
KALTF EXEL KLH PRNAF NURO ISRG K CLVS JNJ SBOT PRAN PBT BMY

13
Clovis Gets EU Acceptance for Rubraca Label Expansion Filing

2018-07-06 zacks
Clovis Oncology, Inc. (CLVS - Free Report) announced that the European Medicines Agency ("EMA") has accepted its type II variation to the marketing authorization seeking label expansion of Rubraca in Europe.
TSRO AZN AZN PFE CLVS

1
Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options

2018-07-06 zacks
Investors in Clovis Oncology, Inc. (CLVS - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $55 Call had some of the highest implied volatility of all equity options today.
ENPH CLVS

0
Clovis Breaks Into Europe With EMA Approval

2018-07-05 247wallst
Clovis Oncology Inc. (NASDAQ: CLVS) shares saw a bump early on Thursday after the company announced that the European Medicines Agency (EMA) has validated its application for a Type 2 variation to the marketing authorization for Rubraca (rucaparib). This validation confirms the submission is complete and begins the EMA’s centralized review process.
CLVS

80
AstraZeneca/Merck's Lynparza Betters Survival in Phase III

2018-06-27 zacks
AstraZeneca (AZN - Free Report) and Merck’s (MRK - Free Report) cancer tablet, Lynparza demonstrated significant delay in disease progression in a late-stage study evaluating it for the first-line treatment of advanced ovarian cancer.
TSRO AZN AZN CLVS

32
Merck and AstraZeneca’s Lynparza Positive in Ovarian Cancer Trial

2018-06-27 biospace
AstraZeneca and Merck announced positive results from their Phase III SOLO-1 clinical trial of Lynparza (olaparib) in BRCA-mutated (BRCAm) advanced ovarian cancer.
CLVS

32
CLVS / Clovis Oncology, Inc. / Palo Alto Investors, LLC - null (Passive Investment)

2018-06-25 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CLVS

32
CLVS / Clovis Oncology, Inc. / Palo Alto Investors, LLC - null (Passive Investment)

2018-06-25 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CLVS

42
Tesaro: Was That The Bottom?

2018-06-25 seekingalpha
Oncology concern Tesaro had a big run up last week on buyout speculation and a positive analyst mention.
TSRO CLVS

93
Immunomedics: Short Term Risk, Long Term Opportunity

2018-06-13 seekingalpha
Immunomedics (NASDAQ:IMMU) is a clinical stage biotech pharmaceutical company specializing in cancer therapies. A market cap near $4.2 billion shows a tremendous amount of optimism about the company's leading drug candidate. The key question at this point is whether the submission of available data to the FDA will result in an early approval, or whether a Phase 3 trial will be necessary. The current market cap seems to assume approval, so the short-term risk is to the downside.
SGEN IMMU CLDX CLVS

38
Pfizer Gains Priority Review For Breast Cancer Drug, Can It Succeed?

2018-06-10 seekingalpha
Pfizer obtains priority review for talazoparib in treating patients with germline BRCA-mutated breast cancer, with FDA decision date by December 2018.
PFE CLVS

42
Sanofi, Gilead said to be eyeing potential $10B deal for prime cancer target Tesaro | FiercePharma

2018-06-08 fiercepharma
Earlier this month, industry watchers questioned who could swallow the reportedly on-the-block Tesaro and its $7.5 billion-plus market cap. Now, though, it seems a pair of M&A-starved drugmakers may be interested in trying.
GILD CLVS

47
CLVS / Clovis Oncology, Inc. FORM 8-K (Current Report)

2018-06-07 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
CLVS

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to CLVS / Clovis Oncology, Inc. on message board site Silicon Investor.

Clovis Onconlogy - CLVS
CUSIP: 189464100